INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

IN8BIO, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$1.09−0.02 (-1.80%)

Close on Oct 19, 2026

Market cap: $21.22M
P/E (TTM): –
Dividend yield: –

IN8BIO, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q3 2021 2021-09-30	Q2 2021 2021-06-30	Q1 2021 2021-03-31	Q4 2020 2020-12-31	Q3 2020 2020-09-30	Q2 2020 2020-06-30	Q1 2020 2020-03-31
Research & Development	2.49	2.61	2.65	2.10	2.49	2.97	3.59	3.31	5.16	4.90	4.52	3.79	4.13	4.39	3.92	4.26	3.50	2.38	2.69	1.35	2.06	1.25	1.49	1.06	1.78	–
General & Administrative	2.44	2.65	2.39	1.86	2.71	2.69	2.63	2.73	3.53	3.74	3.08	3.38	3.58	3.47	3.88	3.14	3.68	3.76	3.16	2.04	0.99	1.12	0.83	0.62	1.09	–
Operating Expenses	4.94	5.27	5.03	3.97	5.20	5.66	6.22	7.11	8.69	8.65	7.60	7.17	7.72	7.86	7.80	7.40	7.18	6.15	5.85	3.39	3.05	2.36	2.31	1.68	2.87	–
Operating Income	-4.78	-5.09	-4.94	-3.85	-5.09	-5.55	-6.16	-7.09	-8.63	-8.56	-7.60	-7.17	-7.72	-7.53	-7.80	-7.40	-7.18	-6.15	-5.85	-3.39	-3.05	-2.36	-2.31	-1.68	-2.87	–
Interest & Investment Income	0.15	0.18	0.09	0.11	0.11	0.11	0.06	0.02	0.06	0.08	0	0	0	0	–	–	–	–	–	–	–	–	–	–	–	–
Merger & Restructuring Charges	–	–	–	–	–	1.10	0	1.10	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–	–	–	0	–
Net Income incl. Noncontrolling Interests	-4.78	-5.09	-4.94	-3.85	-5.09	-5.55	-6.16	-7.09	-8.63	-8.56	-7.60	-7.17	-7.72	-7.53	-7.80	-7.40	-7.18	-6.15	-5.85	-3.39	-3.05	-2.36	-2.31	-1.68	–	–
Net Income	-4.78	-5.09	-4.94	-3.85	-5.09	-5.55	-6.16	-7.09	-8.63	-8.56	-7.60	-7.17	-7.72	-7.53	-7.80	-7.40	-7.18	-6.15	-5.85	-3.39	-3.05	-2.36	-2.31	-1.68	-2.87	-1.69
Preferred Dividends	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0	0.72	0.71	0.72	0.50	0.30	–
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-7.40	-7.18	-6.15	-5.85	-3.39	-3.77	-3.07	-3.03	-2.18	-3.18	–
EPS (Basic)(per share)	-0.25	-0.26	-0.70	-0.85	-1.24	-2.16	-2.37	-4.49	-5.51	-6.00	-6.58	-6.90	-8.10	-9.00	-9.53	-10.20	-11.40	-9.90	–	-7.50	-30.00	-24.60	-26.37	-18.00	-27.60	–
EPS (Diluted)(per share)	-0.25	-0.26	-0.70	-0.85	-1.24	-2.16	-2.37	-4.49	-5.51	-6.00	-6.58	-6.90	-8.10	-9.00	-9.53	-10.20	-11.40	-9.90	–	-7.50	-30.00	-24.60	-26.37	-18.00	-27.60	–
Shares Outstanding (Basic, Weighted)(shares)	19	19	7.10	4.54	4.12	2.58	2.59	1.58	1.57	1.44	1.15	1.05	0.95	0.82	0.82	0.72	0.63	0.63	0.63	0.45	0.13	0.13	0.11	0.12	0.12	–
Shares Outstanding (Diluted, Weighted)(shares)	19	19	7.10	4.54	4.12	2.58	2.59	1.58	1.57	1.44	1.15	1.05	0.95	0.82	0.82	0.72	0.63	0.63	0.63	0.45	0.13	0.13	0.11	0.12	0.12	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -92.5%

Financial strength

Current ratio: 8.21
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 796.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.16
Dividend yield: –